Supported by grants NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) DK068181, DK033506, DK043351 and a research grant from Antisoma, Inc.
1536-4844/asset/IBD_left.gif?v=1&s=9aca2b5041534c51cac4bb66560294c77a457a07)
1536-4844/asset/IBD_right.gif?v=1&s=402e3e241083497ae622916e85e47f64138255a4)
Original Article
You have full text access to this OnlineOpen article
Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammation†
Article first published online: 21 MAR 2011
DOI: 10.1002/ibd.21646
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Additional Information
How to Cite
Sidhu, M., Cotoner, C. A., Guleng, B., Arihiro, S., Chang, S., Duncan, K. W., Ajami, A. M., Chau, M. and Reinecker, H.-C. (2011), Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammation. Inflamm Bowel Dis, 17: 2416–2426. doi: 10.1002/ibd.21646
- †
Publication History
- Issue published online: 9 NOV 2011
- Article first published online: 21 MAR 2011
- Manuscript Accepted: 3 JAN 2011
- Manuscript Received: 23 DEC 2010
REFERENCES
- 1. Inflammatory bowel disease (1). N Engl J Med. 1991; 325: 928–937.
- 2, , . The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007; 117: 514–521.
- 3, , . The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002; 20: 495–549.
- 4
- 5, , , et al. Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbiol. 2008; 10: 1–8.
- 6, , , et al. Nod-like receptors: cytosolic watchdogs for immunity against pathogens. PLoS Pathog. 2007; 3: e152.
- 7. Toll-like receptor signaling. J Biol Chem. 2003; 278: 38105–38108.
- 8, , . Pathogen recognition and innate immunity. Cell. 2006; 124: 783–801.
- 9, . Toll-like receptors in innate immunity. Int Immunol. 2005; 17: 1–14.
- 10, , , et al. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene. 1991; 6: 1641–1650.
- 11. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Curr Opin Hematol. 2001; 8: 149–154.
- 12, , , et al. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol. 1998; 161: 2817–2824.
- 13, . Flt3 ligand (FL) and its influence on immune reactivity. Cytokine. 2000; 12: 87–100.
- 14, , , et al. Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment. Blood. 2009; 113: 6277–6287.
- 15, , , et al. In vivo analysis of dendritic cell development and homeostasis. Science. 2009; 324: 392–397.
- 16, , . Fms-like tyrosine kinase 3-based immunoprophylaxis against infection is improved by adjuvant treatment with anti-interleukin-10 antibody. J Infect Dis. 2005; 192: 693–702.
- 17, , , et al. Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours. Eur J Cancer. 2010; 46: 729–734.
- 18, , , et al. 59th American Academy of Neurology (AAN) Annual Meeting 2007.
- 19, , , et al. Role of blood- and tissue-associated inducible nitric-oxide synthase in colonic inflammation. Am J Pathol. 2007; 170: 490–496.
- 20. Bone marrow derived macrophages (BMM): isolation and applications. Cold Spring Harb Protoc. 2008.
- 21, , . Development of small-molecule therapies for autoimmune diseases. Autoimmunity. 2010; 43: 526–538.
- 22, , , et al. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol. 2006; 177: 7551–7558.
- 23, , . Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. J Immunol. 2002; 169: 3606–3612.
- 24, , . Intestinal macrophages: differentiation and involvement in intestinal immunopathologies. Semin Immunopathol. 2009; 31: 171–184.
- 25, , , et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993; 94: 174–181.
- 26, , . Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 4280–4288.
- 27, , , et al. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther. 2010; 31: 553–560.
- 28, , , et al. Biological therapies for inflammatory bowel disease: research drives clinics. Mini Rev Med Chem. 2006; 6: 771–784.
- 29, , , et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004; 126: 989–996; discussion 947.
- 30, , , et al. Role of interleukin 1 in inflammatory bowel disease—enhanced production during active disease. Gut. 1990; 31: 686–689.
- 31, . Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment Pharmacol Ther. 1996; 10( suppl 2): 49–53; discussion 54.
- 32
- 33, , , et al. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis. 1999; 5: 262–270.
- 34, , , et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000; 119: 1473–1482.
- 35, , , et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut. 2002; 50: 191–195.
- 36, , , et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003; 278: 8869–8872.
- 37, . NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol. 2003; 3: 371–382.
- 38, , , et al. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell. 2007; 25: 713–724.
- 39, . Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369: 1641–1657.
- 40, , , et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol. 2004; 34: 2052–2059.
- 41, , , et al. The TLR2-MyD88-NOD2-RIPK2 signalling axis regulates a balanced pro-inflammatory and IL-10-mediated anti-inflammatory cytokine response to Gram-positive cell walls. Cell Microbiol. 2008; 10: 2067–2077.
- 42, , , et al. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol. 2009; 10: 471–479.